-
Something wrong with this record ?
Radiation-associated angiosarcoma of the breast: An international multicenter analysis
J. Mergancová, A. Lierová, O. Coufal, J. Žatecký, B. Melichar, I. Zedníková, J. Mergancová, A. Jesenková, K. Šťastný, J. Gatěk, O. Kubala, J. Prokop, D. Dyttert, M. Karaba, I. Schwarzbacherová, A. Humeňanská, J. Šuk, M. Valenta, V. Moucha, L....
Language English Country Netherlands
Document type Journal Article, Multicenter Study
- MeSH
- Radiotherapy, Adjuvant * adverse effects MeSH
- Adult MeSH
- Hemangiosarcoma * radiotherapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Mastectomy MeSH
- Breast Neoplasms * radiotherapy MeSH
- Neoplasms, Radiation-Induced * epidemiology MeSH
- Follow-Up Studies MeSH
- Retrospective Studies MeSH
- Mastectomy, Segmental MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
INTRODUCTION: Radiation-associated angiosarcoma (RAAS) is a rare and serious complication of breast irradiation. Due to the rarity of the condition, clinical experience is limited and publications on this topic include only retrospective studies or case reports. MATERIALS AND METHODS: All patients diagnosed with RAAS between January 2000 and December 2017 in twelve centers across the Czech Republic and Slovakia were evaluated. RESULTS: Data of 53 patients were analyzed. The median age at diagnosis was 72 (range 44-89) years. The median latency period between irradiation and diagnosis of RAAS was 78 (range 36-172) months. The median radiation dose was 57.6 (range 34-66) Gy. The whole breast radiation therapy with radiation boost to the tumor bed was the most common radiotherapy regimen. Total mastectomy due to RAAS was performed in 43 patients (81%), radical excision in 8 (15%); 2 patients were not surgically treated due to unresectable disease. Adjuvant chemotherapy followed surgical therapy of RAAS in 18 patients, 3 patients underwent adjuvant radiotherapy. The local recurrence rate of RAAS was 43% and the median time from surgery to the onset of recurrence was 7.5 months (range 3-66 months). The 3-year survival rate was 56%, the 5-year survival rate was only 33%. 46% of patients died during the follow-up period. CONCLUSION: The present data demonstrate that RAAS is a rare condition with high local recurrence rate (43%) and mortality (the 5-year survival rate was 33%.). Early diagnosis of RAAS based on biopsy is crucial for treatment with radical intent. Surgery with negative margins constitutes the most important part of the therapy; the role of adjuvant chemotherapy and radiotherapy is still unclear.
1th Surgical Department General University Hospital Prague Prague Czech Republic
Charles University Faculty of Medicine in Hradec Králové Hradec Králové Czech Republic
Department of Oncology and Radiotherapy University Hospital Pilsen Pilsen Czech Republic
Department of Oncology EUC Clinic Zlín Zlín Czech Republic
Department of Oncology Pardubice General Hospital Pardubice Czech Republic
Department of Oncology University Hospital Olomouc Olomouc Czech Republic
Department of Pathology Liberec General Hospital Liberec Czech Republic
Department of Pathology Pardubice General Hospital Pardubice Czech Republic
Department of Pathology St Elizabeth Cancer Institute Bratislava Slovak Republic
Department of Radiation and Clinical Oncology Liberec General Hospital Liberec Czech Republic
Department of Radiooncology St Elizabeth Cancer Institute Bratislava Slovak Republic
Department of Surgery EUC Clinic Zlín Zlín Czech Republic
Department of Surgery Hospital AGEL Ostrava Vítkovice Ostrava Czech Republic
Department of Surgery Liberec General Hospital Liberec Czech Republic
Department of Surgery Pardubice General Hospital Pardubice Czech Republic
Department of Surgery Silesian Hospital in Opava Opava Czech Republic
Department of Surgery University Hospital Ostrava Ostrava Czech Republic
Department of Surgery University Hospital Pilsen Pilsen Czech Republic
Department of Surgical Oncology Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Surgical Oncology Masaryk University Faculty of Medicine Brno Czech Republic
Department of Surgical Oncology St Elizabeth Cancer Institute Bratislava Slovak Republic
Faculty of Medicine and Dentistry Palacký University Olomouc Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018669
- 003
- CZ-PrNML
- 005
- 20231026104146.0
- 007
- ta
- 008
- 220720s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.suronc.2022.101726 $2 doi
- 035 __
- $a (PubMed)35203019
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Mergancová, Jana $u Department of Surgery, Pardubice General Hospital, Pardubice, Czech Republic; Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
- 245 10
- $a Radiation-associated angiosarcoma of the breast: An international multicenter analysis / $c J. Mergancová, A. Lierová, O. Coufal, J. Žatecký, B. Melichar, I. Zedníková, J. Mergancová, A. Jesenková, K. Šťastný, J. Gatěk, O. Kubala, J. Prokop, D. Dyttert, M. Karaba, I. Schwarzbacherová, A. Humeňanská, J. Šuk, M. Valenta, V. Moucha, L. Sákra, A. Hlávka, M. Hácová, R. Vojtíšek, M. Sochor, T. Jirásek, M. Zábojníková, M. Zemanová, K. Macháleková, D. Rusnáková, E. Kúdelová, M. Smolár
- 520 9_
- $a INTRODUCTION: Radiation-associated angiosarcoma (RAAS) is a rare and serious complication of breast irradiation. Due to the rarity of the condition, clinical experience is limited and publications on this topic include only retrospective studies or case reports. MATERIALS AND METHODS: All patients diagnosed with RAAS between January 2000 and December 2017 in twelve centers across the Czech Republic and Slovakia were evaluated. RESULTS: Data of 53 patients were analyzed. The median age at diagnosis was 72 (range 44-89) years. The median latency period between irradiation and diagnosis of RAAS was 78 (range 36-172) months. The median radiation dose was 57.6 (range 34-66) Gy. The whole breast radiation therapy with radiation boost to the tumor bed was the most common radiotherapy regimen. Total mastectomy due to RAAS was performed in 43 patients (81%), radical excision in 8 (15%); 2 patients were not surgically treated due to unresectable disease. Adjuvant chemotherapy followed surgical therapy of RAAS in 18 patients, 3 patients underwent adjuvant radiotherapy. The local recurrence rate of RAAS was 43% and the median time from surgery to the onset of recurrence was 7.5 months (range 3-66 months). The 3-year survival rate was 56%, the 5-year survival rate was only 33%. 46% of patients died during the follow-up period. CONCLUSION: The present data demonstrate that RAAS is a rare condition with high local recurrence rate (43%) and mortality (the 5-year survival rate was 33%.). Early diagnosis of RAAS based on biopsy is crucial for treatment with radical intent. Surgery with negative margins constitutes the most important part of the therapy; the role of adjuvant chemotherapy and radiotherapy is still unclear.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 12
- $a nádory prsu $x radioterapie $7 D001943
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a hemangiosarkom $x radioterapie $7 D006394
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mastektomie $7 D008408
- 650 _2
- $a segmentální mastektomie $7 D015412
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 12
- $a nádory vyvolané zářením $x epidemiologie $7 D009381
- 650 12
- $a adjuvantní radioterapie $x škodlivé účinky $7 D018714
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Lierová, Anna $u Faculty of Health Studies, Department of Clinical Subspecialities, University of Pardubice, Pardubice, Czech Republic
- 700 1_
- $a Coufal, Oldřich $u Department of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Surgical Oncology, Masaryk University, Faculty of Medicine, Brno, Czech Republic
- 700 1_
- $a Žatecký, Jan $u Department of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Surgery, Silesian Hospital in Opava, Opava, Czech Republic
- 700 1_
- $a Melichar, Bohuslav $u Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic; Department of Oncology, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Zedníková, Ilona $u Department of Surgery, University Hospital Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Mergancová, Jindřiška $u Department of Surgery, Pardubice General Hospital, Pardubice, Czech Republic
- 700 1_
- $a Jesenková, Anna $u Department of Surgery, Pardubice General Hospital, Pardubice, Czech Republic; Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Šťastný, Karel $u Department of Surgery, Pardubice General Hospital, Pardubice, Czech Republic
- 700 1_
- $a Gatěk, Jiří $u Department of Surgery, EUC Clinic Zlín, Zlín, Czech Republic
- 700 1_
- $a Kubala, Otakar $u Department of Surgery, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Prokop, Jiří $u Department of Surgery, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Dyttert, Daniel $u Department of Surgical Oncology, St. Elizabeth Cancer Institute, Bratislava, Slovak Republic
- 700 1_
- $a Karaba, Marián $u Department of Oncosurgery, National Cancer Institute, Slovak Medical University, Bratislava, Slovak Republic $7 xx0301194
- 700 1_
- $a Schwarzbacherová, Ivana $u 1th Surgical Department, General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Humeňanská, Anna $u Department of Surgery, Hospital AGEL Ostrava-Vítkovice, Ostrava, Czech Republic
- 700 1_
- $a Šuk, Jindřich $u 1th Surgical Department, General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Valenta, Michal $u Department of Surgery, Liberec General Hospital, Liberec, Czech Republic
- 700 1_
- $a Moucha, Vladimír $u Mammological Ambulance, Hořovice, Czech Republic
- 700 1_
- $a Sákra, Lukáš $u Department of Surgery, Pardubice General Hospital, Pardubice, Czech Republic
- 700 1_
- $a Hlávka, Aleš $u Department of Oncology, Pardubice General Hospital, Pardubice, Czech Republic
- 700 1_
- $a Hácová, Mária $u Department of Pathology, Pardubice General Hospital, Pardubice, Czech Republic
- 700 1_
- $a Vojtíšek, Radovan $u Department of Oncology and Radiotherapy, University Hospital Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Sochor, Marek $u Department of Radiation and Clinical Oncology, Liberec General Hospital, Liberec, Czech Republic
- 700 1_
- $a Jirásek, Tomáš $u Department of Pathology, Liberec General Hospital, Liberec, Czech Republic
- 700 1_
- $a Zábojníková, Michaela $u Department of Oncology, EUC Clinic Zlín, Zlín, Czech Republic
- 700 1_
- $a Zemanová, M. $u Department of Radiooncology, St. Elizabeth Cancer Institute, Bratislava, Slovak Republic $7 xx0309039
- 700 1_
- $a Macháleková, Katarína $u Department of Pathology, St. Elizabeth Cancer Institute, Bratislava, Slovak Republic
- 700 1_
- $a Rusnáková, Dominika $u Department of Oncosurgery, National Cancer Institute, Slovak Medical University, Bratislava, Slovak Republic
- 700 1_
- $a Kúdelová, Eva $u Clinic of General, Visceral and Transplant Surgery, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital Martin, Martin, Slovak Republic
- 700 1_
- $a Smolár, Marek $u Clinic of General, Visceral and Transplant Surgery, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital Martin, Martin, Slovak Republic. Electronic address: marino.smolar@gmail.com
- 773 0_
- $w MED00004468 $t Surgical oncology $x 1879-3320 $g Roč. 41, č. - (2022), s. 101726
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35203019 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20231026104140 $b ABA008
- 999 __
- $a ok $b bmc $g 1822339 $s 1169912
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 41 $c - $d 101726 $e 20220216 $i 1879-3320 $m Surgical oncology $n Surg Oncol $x MED00004468
- LZP __
- $a Pubmed-20220720
